Imugene Ltd
IMU
Company Profile
Business description
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its products include HER-Vaxx, PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment is the Research and Development of oncolytic immunotherapies.
Contact
4-6 Bligh Street
Suite 12.01, Level 12
SydneyNSW2000
AUSSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
5
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,775.00 | 4.40 | 0.05% |
| CAC 40 | 7,742.24 | 57.56 | 0.75% |
| DAX 40 | 23,699.12 | 182.89 | 0.78% |
| Dow JONES (US) | 42,466.07 | 268.28 | 0.64% |
| FTSE 100 | 8,875.22 | 24.59 | 0.28% |
| HKSE | 24,060.99 | 168.43 | 0.70% |
| NASDAQ | 19,694.37 | 287.54 | 1.48% |
| Nikkei 225 | 38,311.33 | 477.08 | 1.26% |
| NZX 50 Index | 12,690.13 | 137.26 | 1.09% |
| S&P 500 | 6,027.58 | 50.61 | 0.85% |
| S&P/ASX 200 | 8,548.40 | 1.00 | 0.01% |
| SSE Composite Index | 3,388.73 | 11.73 | 0.35% |